Groups treated with ketotifen + dacarbazine or sonopermeation + dacarbazine showed trends toward reduced tumor mass, though these did not reach statistical significance ( Fig. 3 C).
← all excerpts
Modulating tumor mechanics and vascular barriers to enhance chemotherapy efficacy in pancreatic tumors and melanoma.
3
—
—
The sentences
Ketotifen + oxaliplatin showed a trend toward higher Granzyme B levels compared to control, and sonopermeation + oxaliplatin was significantly elevated relative to both control and oxaliplatin groups.
The levels of IL-10, an immune suppressive cytokine produced by regulatory T cells and Th1 cells [ 100 ], revealed a decreasing trend in the triple therapy group compared to the other groups.